If you have been reading about prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
=== Breastfeeding and the prosthetic breast === The breasts of a woman are apocrine glands that produce breastmilk with which to feed an infant child. A woman with implanted prosthetic breasts can breastfeed an infant, yet the breast implants can interfere with the breastfeeding function, especially in the case of a woman whose breast augmentation surgery accidentally cut into the nipple-areola complex (NAC) and might either have damaged the lactiferous ducts or damaged the nerves that serve the nipple-areola complex.
=== Proposed sovereign state === On 21 September 2024, it was reported that Prime Minister Edi Rama of Albania was planning to create the Sovereign State of the Bektashi Order, a sovereign microstate for the order within the Albanian capital of Tirana. Rama said the aim of the new state would be to promote religious tolerance and a moderate version of Islam.
=== Pilgrim Fathers === A meeting of the Pilgrim Fathers, prior to their sailing in the Mayflower, is said to have taken place on the High Street; many local names and much historical imagery reflect this, such as Mayflower House, Mayflower Morris Men, Mayflower Taxis, Mayflower School and Mayflower Hall. Sunnymede school's houses were called Mayflower, Pilgrim and Chantry. Christopher Martin, who was born in Great Burstead and later became a Billericay goods merchant and property owner, travelled on the Mayflower in 1620; he was the official ship's governor and purchasing agent, procuring ships supplies for the voyage. The Mayflower ship set sail once the Pilgrim Fathers had all boarded and set to meet the Speedwell in the English Channel; the Speedwell was sailing from the Netherlands. Unfortunately, the Speedwell developed leaks and so the ships headed for the Devon coast to repair her, but this proved impossible; the Mayflower eventually sailed from Plymouth without her. Four people from Billericay were on board, including Christopher Martin, his wife Mary Prowe, along with Solomon Prowe - her son from her first marriage - and John Langemore, the Martins' servant. All four pilgrims perished after their arrival at Cape Cod, Massachusetts. Martin died of fever on 8 January 1621 and his wife perished in Plymouth in the same year. Both Christopher and Mary are buried in the Cole Hill Burial ground in Plymouth. The unfortunate fate of the would-be pioneers did not deter other inhabitants of Billericay from setting sail for the New World.
== See also == Abzyme: Antibodies can act as enzymes if they are selected against transition state analogues. Abzymes have a low KM, meaning that they readily bind a target molecule, but have low Vmax values, indicating a slow reaction rate. Biomimetics Bioorthogonal chemistry Catalysis Density functional theory Directed evolution Enzyme Molecular machine Molecularly imprinted polymer Nanochemistry Supramolecular chemistry Zeolite
In 911, Robert I of France, brother of Odo, again defeated another band of Viking warriors in Chartres with his well-trained horsemen. This victory paved the way for Rollo's baptism and settlement in Normandy. The Duchy of Normandy, which began in 911 as a fiefdom, was established by the treaty of Saint-Clair-sur-Epte between King Charles III (Charles the Simple) (879–929, ruled 893–929) of West Francia and the famed Viking ruler Rollo also known as Gaange Rolf (c. 846–c. 929), from Scandinavia, and was situated in the former Frankish kingdom of Neustria. The treaty offered Rollo and his men the French coastal lands along the English Channel between the river Epte and the Atlantic Ocean coast in exchange for their protection against further Viking incursions. As well as promising to protect the area of Rouen from Viking invasion, Rollo swore not to invade further Frankish lands himself, accepted baptism and conversion to Christianity and swore fealty to King Charles III. Robert I of France stood as godfather during Rollo's baptism. He became the first Duke of Normandy and Count of Rouen. The area corresponded to the northern part of present-day Upper Normandy down to the river Seine, but the Duchy would eventually extend west beyond the Seine. The territory was roughly equivalent to the Ecclesiatical province of Rouen, and reproduced the old Roman Empire's administrative structure of Gallia Lugdunensis II (part of the former Gallia Lugdunensis in Gaul).
Sources: en.wikipedia.org
=== Dietary recommendations === The US Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for selenium in 2000. If there is not sufficient information to establish EARs and RDAs, an estimate designated Adequate Intake (AI) is used instead. The current EAR for selenium for people ages 14 and up is 45 μg/day. The RDA is 55 μg/day. RDAs are higher than EARs so as to identify amounts that will cover people with higher-than-average requirements. RDA for pregnancy is 60 μg/day. RDA for lactation is 70 μg/day. For children ages 1–13 years, the RDA increases with age from 20 to 40 μg/day. As for safety, the IOM sets Tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of selenium, the UL is 400 μg/day. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women and men ages 15 and older, the AI is set at 70 μg/day. AI for pregnancy is 70 μg/day; for lactation, 85 μg/day. For children ages 1–14 years, the AIs increase with age from 15 to 55 μg/day. These AIs are higher than the U.S. RDAs. The European Food Safety Authority reviewed the same safety question and set its UL at 300 μg/day, which is lower than the U.S. value.
=== Comparative effectiveness === A major systematic review and network meta-analysis of medications for the treatment of insomnia was published in 2022. It found a widely varying range of effect sizes (standardized mean difference or SMD) in terms of clinical effectiveness for insomnia. The assessed medications and their effect sizes included benzodiazepines (e.g., temazepam, triazolam, many others) (SMDs 0.58 to 0.83), Z-drugs (eszopiclone, zaleplon, zolpidem, zopiclone) (SMDs 0.03 to 0.63), sedative antidepressants and antihistamines (doxepin, doxylamine, trazodone, trimipramine) (SMDs 0.30 to 0.55), the antipsychotic quetiapine (SMD 0.07), orexin receptor antagonists (daridorexant, lemborexant, seltorexant, suvorexant) (SMDs 0.23 to 0.44), and melatonin receptor agonists (melatonin, ramelteon) (SMDs 0.00 to 0.13). The certainty of evidence varied and ranged from high to very low depending on the medication. Certain medications often used as hypnotics, including the antihistamines diphenhydramine, hydroxyzine, and promethazine and the antidepressants amitriptyline and mirtazapine among others, were not included in analyses due to insufficient data.
The definitions of the pressure ulcer stages are revised periodically by the National Pressure Injury Advisory Panel (NPIAP) in the United States and the European Pressure Ulcer Advisory Panel (EPUAP) in Europe. Different classification systems are used around the world, depending upon the health system, the health discipline and the purpose for the classifying (e.g. health care versus, prevalence studies versus funding. Briefly, they are as follows:
The COVID-19 pandemic in North Korea was part of a global pandemic of coronavirus disease 2019 (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). North Korea confirmed its first case on 8 May 2022. North Korea is a secretive and diplomatically isolated country in East Asia. Its weak healthcare system and impoverished population led to concerns over the country's vulnerability to an outbreak, though its cold chain vaccination program had proven capable in prior pandemics. With a totalitarian political system, little information on the pandemic's impacts on North Korea has been available to international observers. In January 2020, the North Korean government began taking extensive measures to protect itself from the initial COVID-19 outbreak, including the establishment of quarantine facilities, and strict travel restrictions. In March and April 2020, the Asia Times and 38 North reported that these measures seemed largely successful. Before May 2022, the government of North Korea had not reported any confirmed cases of COVID-19, although some foreign analysts believed that the virus had spread there by March 2020. Daily NK, a South Korean dissident-run news website, said that about 180 soldiers had possibly died from COVID-19 symptoms in January and February 2020. In July 2020, a single suspected case in Kaesong prompted a three-week lockdown. By 2021, there were increasing reports that the isolation imposed to avoid the pandemic was having a major impact on the economy.
=== Mosaic Viruses === In 1955, Robert Rice and Kaesberg researched why the tobacco mosaic virus breaks apart after preservation via freeze-drying. Although they did not figure out what caused it specifically, their research allowed them to rule out several possibilities. They found that the act of freeze-drying did not cause the virus to break, as freeze-drying did not cause insulin fibrils or flagella to break. In 1956, Kaesberg discovered a new virus shape, the icosahedral shape. After taking electron micrographs of the bromegrass mosaic virus and the yellow turnip mosaic virus under light shadowing and heavy shadowing, respectfully, Kaesberg was able to come up with an icosahedral model of the viruses. This shape became the modern-day symbol for a virus because, after much more research, the icosahedral shape was one of the most commonly found virus shapes. In 1958, Kaesberg and colleagues discovered a mosaic virus found in alfalfa creates three macromolecules after infecting a plant. Only one of the types of particles produced the virus, but all three had a similar bacillus-like shape and size. These particles looked nothing like the known spherical species of the alfalfa mosaic virus, so they discovered a new isolate in their work. In 1964, Paul Kaesberg and a colleague studied the effects of pH changes on the bromegrass mosaic virus. They found that when the environment's pH is higher than 6.7, there is a decrease in the virus’ sedimentation coefficient. The coefficient goes back up if the pH goes below 6.7.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.